Ibrutinib & Venetoclax: Long-Term CLL/SLL Remission
Patients with chronic lymphocytic leukemia (CLL) and small lymphocytic lymphoma (SLL) are seeing lasting benefits from a fixed-duration treatment combining ibrutinib and venetoclax. This groundbreaking regimen shows promise, particularly for those with high-risk genomic features, according to the CAPTIVATE study. With a median follow-up of nearly 69 months, the study revealed a 5.5-year progression-free survival rate of 66% and an overall survival rate of 97%. Genetic risk factors, including del(17p) or mutated TP53, substantially impact outcomes, as do IGHV mutation status and minimal residual disease (MRD) levels. News Directory 3 reports on these findings, noting that even after disease progression, retreatment with ibrutinib proves effective. With remarkable response rates in relapsed settings, this treatment offers new hope. Discover what’s next in CLL/SLL treatment strategies.
Ibrutinib, Venetoclax Combo Shows Promise in CLL/SLL Treatment
Updated June 5, 2025
CHICAGO—A fixed-duration regimen of ibrutinib and venetoclax demonstrates lasting benefits for patients with chronic lymphocytic leukemia (CLL) and small lymphocytic lymphoma (SLL), notably those with high-risk genomic features. The findings, from the phase 2 CAPTIVATE study, were presented at the American Society of Clinical Oncology (ASCO) meeting.
The study involved patients 70 years and younger who received ibrutinib followed by ibrutinib plus venetoclax. Some patients received a placebo.after initial therapy, retreatment with ibrutinib alone or combined with venetoclax was an option for those whose disease progressed after two years.
Of the 202 patients who completed the ibrutinib and venetoclax treatment, the median follow-up was nearly 69 months. Results showed a 5.5-year progression-free survival (PFS) rate of 66% and an overall survival (OS) rate of 97%. However, genetic factors played a meaningful role.Patients without del(17p) or mutated TP53 had a 70% PFS rate, while those with high-risk genomic alterations had only a 36% rate.
IGHV mutation status also affected outcomes. Patients with unmutated IGHV had a 55% PFS rate,while those with mutated IGHV reached 79%. Minimal residual disease (MRD) status strongly correlated with outcomes. Undetectable MRD in peripheral blood was achieved in 54% of patients by cycle 7 and 69% at the end of treatment. Patients with undetectable MRD had a higher 5.5-year PFS rate (75%) compared to those with detectable MRD (47%).
Among the 64 patients who experienced disease progression, retreatment with ibrutinib alone yielded a 76% overall response rate, with 2-year PFS and OS rates of 91% and 96%, respectively. For those retreated with ibrutinib plus venetoclax, the overall response rate was 82%, with 1-year PFS and OS rates of 100%.
During the study, 24 patients developed second malignancies.
What’s next
These findings support the use of fixed-duration ibrutinib and venetoclax as a first-line treatment for CLL/SLL,even in patients with high-risk genomic features. The durable responses seen with ibrutinib-based retreatment suggest its potential in relapsed settings following initial fixed-duration therapy. Further studies are needed to refine treatment strategies and manage the risk of second malignancies.